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Idiopathic membranous nephropathy: The natural history of untreated
patients. We reviewed the diagnostic features and clinical course of 140
patients with idiopathic membranous nephropathy who had their index
renal biopsies performed at the Mayo Clinic between 1972 and 1984.
There were 93 males and 47 females (average age, 50.8 17 years); 116
patients (83%) had the nephrotic syndrome and 42 (30%) were hyper-
tensive at diagnosis. Eighty-nine patients were not treated with corti-
costeroid or immunosuppressive drugs and 51 patients were treated
mainly with short-term courses of prednisone alone; a minority of
patients also received meclofenamate, cyclophosphamide. azathio-
prine, or chlorambucil. Five-year survival, including patients who
received dialysis or a renal transplant, was 85%, 75% at 10 years. and
no different from expected survival; there was no difference between
untreated and treated groups. Also, there were no differences in the
outcomes of renal function and protein excretion between untreated
and treated patients. Among 28 patients (20%) who developed end-stage
renal disease, 17 showed rapid progression within 2.5 years after
diagnosis. Fifteen of the 17 patients were males; all were severely
nephrotic and had impaired renal function at diagnosis. Only 1 of 24
patients with nonnephrotic proteinuria at index renal biopsy progressed
to end-stage renal disease. Overall, a level of baseline proteinuria of 10
g or more per 24 hours and variable blood pressure control in hyper-
tensive patients were associated with renal progression.
As a form of primary glomerulopathy with a well-defined
histologic appearance, idiopathic membranous nephropathy is
most common in adults with the nephrotic syndrome. Although
there are distinctive morphologic and immunopathologic char-
acteristics, the glomerular lesion most likely represents a con-
stellation of different disease processes [1, 21.
Progression to renal failure varies widely in analyses of large
numbers of both untreated and treated patients worldwide
[3—12]. Variations in clinical course undoubtedly stem from
poorly understood causes and pathogenesis. There are also
recognized clinical observations of better outcomes, particu-
larly in women [13], children [5], and those who have non-
nephrotic proteinuria at presentation, as opposed to a worse
prognosis in patients who present with the nephrotic syndrome
[4, 7, 101. Association of idiopathic membranous nephropathy
with HLA DR3 has been found in populations from England,
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Germany, and Spain and with HLA DR2 in Japan [14, 151. A
benign clinical course has been reported in Japanese patients
[151. On the other hand, patients from England with the
haplotype Bl8-BfFI-DR3 had a worse prognosis than others
[14]. All of these conditions must be taken into consideration
when evaluating the effects of various therapies on clinical
outcome.
The treatment of idiopathic membranous nephropathy re-
mains controversial [16, 17]. Eight prospective, controlled,
clinical trials have been published, more than in any of the other
primary glomerular diseases [18—251. Four studies failed to
show effectiveness of several treatments [18—2 1] and four
reported beneficial effects [22—25].
We report our long-term observations on 140 patients with
idiopathic membranous nephropathy, 89 of whom did not
receive treatment with either corticosteroid or immunosuppres-
sive drugs. Reviewing the natural history of idiopathic membra-
nous nephropathy is particularly important in view of the
unsettled issue of therapeutic intervention.
Methods
Selection of patients
Renal biopsies from 170 patients with membranous nephrop-
athy who had their index biopsies at the Mayo Clinic between
1972 and 1984 were examined. To ensure a uniform approach to
histologic diagnosis, tissue blocks of light microscopic sections
and tissue for immunofluorescent- and electron-microscopy
were prepared by standard techniques [26].
Staging of the glomerular morphology by electron micros-
copy followed that advocated by Ehrenreich and Churg [27] and
Churg [28]. Each renal biopsy specimen was graded by two of
us (M.O. and K.E.H.) without prior clinical knowledge of the
case. When an inadequate or a nonrepresentative sample of
glomeruli was available from the original electron microscopy
studies, additional tissue was prepared for electron microscopic
examination by using previously paraffin-embedded tissue. Fi-
nal assignment of a given case to a certain stage represented a
composite or sum of the most prominent lesions seen in the
glomeruli examined. For example, in stage II and III lesions,
small segments of basement membranes with few or no subepi-
thelial deposits were commonly found with no or little alter-
ations of the lamina densa. Also, occasional loops in a stage II
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lesion showed isolated deposits exhibiting reabsorption of de-
posits. More advanced stage IV lesions showed individual
segments of capillary wall with stage I, II, or III lesions. In
cases in which the given lesions of stages II and III or stages III
and IV were equal, the assignment of the lesion was to the
highest category.
Five stages of development were defined as follows:
Stage I. Small deposits were scattered along subepithelial
surfaces of the basement membranes; there were focal conflu-
ence of deposits, an absence of rudimentary basement mem-
brane reaction (spikes), and lamina densa of normal thickness.
Stage II. Large numbers of subepithelial deposits (many
confluent) were located along most peripheral capillary loops;
there were deposits indenting lamina densa and prominent
spikes with infrequent incorporation of deposits.
Stage III. There was a large number of subepithelial depos-
its, prominent incorporation of deposits into thickened lamina
densa, and reabsorption of deposits was well-defined.
Stage IV. Stage IV lesions showed markedly thickened
lamina densa with variable electron densities and segments of
basement membranes which may contain lesions of stage I, II,
or III.
Stage V or end-stage. This had capillary wall collapse and
global sclerosis with some loops showing lesions of stage I, II,
or III.
In seven biopsies electron microscopic examination was not
available so that staging of the glomerular lesion was based on
assessment of the thin-section light microscopy.
Details of patients
The histories of those patients with histologically defined
membranous nephropathy were reviewed. Twenty-four pa-
tients were excluded from study for the following reasons:
systemic diseases of lupus erythematosus (6) and rheumatoid
arthritis (6)—in the latter, associations with gold-salt treatment
(3) and gold-salt plus D-penicillamine treatment (2); other dis-
orders including crescentic glomerulonephritis superimposed
on membranous nephropathy (2), bullous pemphigoid (2), lym-
phoproliferative disease (2), cryoglobulinemia (I), idiopathic
thrombocytopenic purpura, Coombs'-positive hemolytic ane-
mia, and IgG kappa monoclonal proteinemia (I), myasthenia
gravis(1), polyarteritis nodosa(l), pyodermagangrenosum (1),
polymyalgia rheumatica and gold-salt treatment (I). Four pa-
tients with idiopathic membranous nephropathy were excluded
from analysis because they presented with renal failure: three
were dialysis dependent and one patient had a serum creatinine
level of 8.2 mg/dl and progressed to dialysis treatment in four
weeks. No follow-up information after renal biopsy was ob-
tained for two patients. Thus, 140 patients with idiopathic
membranous nephropathy comprised the study group. Patients
were followed at varying intervals in this retrospective clinical
review.
Baseline laboratory data at index renal biopsy were analyzed
with respect to urinalysis, concentrations of serum creatinine,
cholesterol and triglycerides, serum protein electrophoresis,
serologies including hepatitis B surface antigen, antinuclear
antibodies, CHs), C3, 24-hour creatinine clearance (Car) and
total protein excretion, and clearance of iothalamate (C10).
Standard techniques of the Mayo Clinic clinical laboratories
were used in each instance.
If recent clinical or laboratory data were not available from
personal examination at the Mayo Clinic, a local physician or
the patient was contacted to ascertain information that included
determination of blood pressure; treatments used for hyperten-
sion, the nephrotic syndrome, and the glomerulopathy; and
return of serum and 24-hour urine samples for measurement of
Cr and total urine protein.
Among the 140 patients, 89 were not treated with cortico-
steroid, immunosuppressive, or other drugs. Fifty-one patients
were treated as follows: prednisone alone (33), pre-index biopsy
(13), and post-index biopsy (20). Prednisone was administered
before or in combination with other drugs as follows: meclo-
fenamate (9), oral cyclophosphamide (3), azathioprine (1), and
chlorambucil (1). Meclofenamate was used in a prospective
study of severe nephrotic syndrome that included nine patients
in this review [29]. Nineteen patients were receiving prednisone
at the time of their index renal biopsy. Minimal prednisone
treatment was with 40 mg/day for one month in two patients; 18
received prednisone at a dosage of 60 mg/day for two months or
longer, and the remainder of those who were given prednisone,
either alone or combined with an immunosuppressive agent,
took 20 to 40 mg/day for 6 to 24 months. Cyclophosphamide
alone was given to four patients in a dosage of 2 mg/kg per day
for one year [20].
Hypertension was treated with a wide variety of antihyper-
tensive agents and sodium restriction, usually to less than 90
mEq/day, and various diuretic regimens were given for hyper-
tension and control of edema.
Criteria for patient assessment
Particular attention was paid to certain arbitrarily defined
criteria of outcome. For renal function: 1) stable (serum creat-
mine within 0.3 mg/dl from baseline); 2) renal insufficiency
(serum creatinine, 2 to 5 mg/dl); and 3) renal failure (serum
creatinine, >5 mg/dl). For proteinuria: I) nephrotic syndrome
(proteinuria, >3.5 g/24 hr, and lipiduria) or persistent protein-
uria (>2 g/24 hr) and 2) remission of nephrotic syndrome (either
partial [urine protein, 0.2 to 2 g/24 hrl or complete [urine
protein, <0.2 g/24 hr]). For deaths, the date of death and cause
were recorded and included a review of autopsy reports when
available.
Data analysis
Clinical data forms were completed and the information was
placed on magnetic tapes for analysis by using SAS (Statistical
Analysis Systems) software. Data were then analyzed in the
Section of Medical Research Statistics at the Mayo Clinic
(DM1. and C.-P.C.). Patient and kidney survival were esti-
mated by survivorship analysis by using the method of Kaplan
and Meier [30]. The relationship of covariates to patient and to
kidney survival was investigated univariately with the log-rank
test [31], and multivariately with the Cox proportional-hazards
model [32]. Sufficient data to test in the multivariate procedure
included age, sex, systolic and diastolic blood pressure, serum
creatinine, 24-hour urine protein, serum cholesterol, and tri-
glyceride levels. Discrete variables were compared in untreated
and treated groups with ,2 tests, and continuous variables were
compared with t-tests or with rank-sum procedures.
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Clinical features
Sex, M:F
Age, yr (mean SD)
Median duration of proteinuria
months
Blood pressure mm Hg
Systolic (mean SD)
Diastolic (mean SD)
Stage of index renal biopsy
II
III
Iv
Total
Laboratory findings (mean SD)
Serum creatinine mg/dl
Cr mI/mm 1.73 m2 (N = 43)
C10 mI/mm 1.73 m2 (N = 62)
Proteinuria g/24 hr
Serum
Albumin gidI
Total protein gidI
Cholesterol mg/dl
Triglycerides mg/dl
a p < 0.05
56:33
50.8 17
3
143 23
86 12
No. (%)
7 (8)
64 (72)
17 (19)
1(1)
89 (100)
1.3 0.6
84 39
75 31
8.2 5.2
2.3 0.6
5.3 ÷ 0.8
373 124
228 149
Treated
N = SI
37:14
49.7 17
5
142 20
87 10
No. (%)
5 (10)
36 (71)
10 (20)
0 (0)
51(100)
1.2 0.5
80 29
81 30
8.7 6.1
2.2 0.7
5.1 0.8
400 122
279 162
Results
The clinical features of the 140 patients at index renal biopsy
are listed in Table 1. There was a male to female ratio of 2:1; the
average age was 50.4 16.8 years, and 24 patients (17%) were
less than 30 years old. One hundred sixteen of 140 patients
(83%) had the nephrotic syndrome at presentation, including 43
patients (31%) whose baseline proteinuria exceeded 10 g124
hour. Forty-two patients (30%) were hypertensive. One hun-
dred twenty-four patients (89%) were followed from the time of
index renal biopsy to current status (within the past 12 months),
end-stage renal disease, or death. Follow-up information to
current status was incomplete in 16 patients. For the entire
study group, follow-up was 0.2 to 14.3 years (mean, 6.2 years;
median, 6.1 years).
Histologic staging of the index renal biopsies is shown in
Table 2. The majority of the biopsies were classified as well-
developed or stage II lesions. To emphasize the overlapping
found on electron microscopic examination, 66 biopsy speci-
mens were further designated within major stages as 28 early
and 31 late II lesions and 7 late III lesions.
Multiple clinical variables were analyzed between untreated
and treated groups (Table 3) and were not significantly different
for sex, age, duration of proteinuria, hypertension, stage of the
index renal biopsy, or baseline laboratory findings, including
serum creatinine level, CCr, Clot, 24-hour urine protein, or
levels of serum albumin, total protein, and cholesterol. Mean
serum triglyceride level was higher in treated patients (P <
0.05). As there were 19 patients receiving prednisone at the time
baseline data were collected, the elevated triglyceride level
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Fig. 1. Survival ofpatients with idiopathic membranous nephropat/ty.
A. Comparison with survival of age- and sex-matched upper midwest
(Life table) population. Symbols are: (—) Life table population; (—) all
patients. B. Comparing untreated (—, N = 89) and treated patients(—, N 51).
relates to the effect of corticosteroids on increased lipoprotein
production and reduced lipoprotein lipase activity mainly af-
fecting very low density lipoproteins [33].
Patient survival for the total, the untreated, and the treated
groups is shown in Figure 1. The overall survival was 85% at 5
years and 75% at 10 years; these were not significantly different
from normal, and there was no significant difference between
nontreatment and treatment groups. Survival without death or
renal failure was 71% at 5 years, 58% at 10 years, and although
about 10 percentage points higher in untreated patients, not
significantly different from the treated group (Fig. 2).
The outcome of renal function according to criteria based on
serum creatinine data shows no significant differences in the
categories of stable, end-stage renal disease, or renal insuffi-
ciency outcomes between untreated and treated groups (Table
4). Overall, for the 140 patients, 90 (64%) remained stable, 28
Table 1. Clinical features at index renal biopsy in 140 patients with
idiopathic membranous nephropathy
Table 3. Clincial variables at diagnosis in untreated and treated
patients with idiopathic membranous nephropathy
Males 93
Females 47
Age yr
Range 11—81
Mean (±so) 50.4 16.8
Median 54
24 patients (17%) < 30
Duration of proteinuria months
Range 0—540
Median 4
Newly discovered, 26 patients (19%)
Nephrotic syndrome no. of patients
116 (83%); baseline proteinuria >3.5 g/24 hr + lipiduria
43(31%) had baseline proteinuria >10 g/24 hr
Hypertension (BP >150/90 mm Hg), no. of patients 42 (30%)
Newly discovered (15 patients) to 20 yr duration
Untreated
N = 89
Table 2. Composite histologic stage of index renal biopsies in 140
patients with idiopathic membranous nephropathy
Composite histologic
stage Biopsies, no. %
I 12 8.6
II 100 71.4
III 27 19.3
IV 1 0.7
V Q 0
Total 140 100
a Severe arterial/arteriolar sclerosis in 33 biopsies (24%)
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Fig. 2. Survival without death or rena/failure in untreated (—, N = 89)
and treated (—, N = 51) patients with idiopathic inembranous
nephropathy.
Table 4. Outcome of renal function by serum creatinine data in
untreated and treated patients with idiopathic membranous
nephropathy
Group
Serum creatinine
Renal
insufficiency,
2-5 mg/dl no.
(%)
Untreated
N = 89 60(67) 16(18) 13 (15)
Treated
N = 51 30 (59) 12 (24) 9 (18)
Total 90 (63) 28 (21) 22 (16)
E
(0
C
(0(0
0
E
a)
U)
(20%) developed end-stage renal disease, and 22 (16%) had
renal insufficiency at last analysis. The time course to renal
failure found by plotting serum creatinine values from baseline
to end-stage renal disease (first serum creatinine level >5 mg/dl)
was not different comparing untreated and treated groups. In
the 16 untreated patients, the time course to end-stage renal
disease was 3.9 1.4 years and in the 12 treated patients it was
3.2 0.8 years.
For the 28 patients who progressed to end-stage renal dis-
ease, the values for serum creatinine over time are plotted in
Figure 3. In 17 patients (11 untreated, 6 treated) progression to
end-stage renal disease occurred in 2.5 years or less after index
renal biopsy. Clinical variables associated with this rapid pro-
gression were male gender, elevated serum creatinine levels,
and nephrotic syndrome (24-hour urine protein, serum choles-
terol, and triglycerides) (Table 5). There were no significant
differences between untreated and treated groups. We did not
find an association between rapid progression and age, stage of
the index renal biopsy, baseline systolic and diastolic blood
pressures, serum proteins, Cc., or C1)). Renal function by
clearance measurements were made in fewer patients than were
estimates by serum creatinine determinations. In the Ii patients
with more gradual progression to end-stage renal disease, six
were males, five were females, and all were nephrotic at
presentation and throughout their clinical course.
By multivariate analysis, serum creatinine and 24-hour urine
protein levels (P < 0.01) and serum triglyceride concentrations
Table 6. Outcome of proteinuria at last follow-up in 116 patients with
nephrotic syndrome and idiopathic membranous nephropathy
Group Patientsa
no. (%)
Untreated, N = 72
Remission 41(57)
Persistent proteinuria 7 (10)
Nephrotic syndrome 24 (33)
Treated, N 42
Remission 17 (40)
Persistent proteinuria 5 (12)
Nephrotic syndrome 20 (48)
a Nephrotic syndrome was intermittent in 17 patients (15%) with
various outcomes, including 8 nephrotics, 7 remissions, and 2 with
nonnephrotic proteinuria. Urine protein was not quantified for 24-hour
measurement in 2 untreated patients so that follow-up information to
last analysis is available in 114 patients.
(P < 0.03) remained significantly associated with progression to
end-stage renal disease.
The outcome of proteinuria in the 116 nephrotic patients as
judged by the defined criteria for patient assessment showed no
differences in the nontreatment and treatment groups (Table 6).
The majority, or 41 of 72(57%), of untreated patients and 17 of
42 (40%) treated patients had achieved either partial or com-
plete remission from the nephrotic syndrome at final assess-
ment. The nephrotic syndrome was intermittent in 17 patients
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Fig. 3. Serum creatinine over time Jr the 28 patients who developed
end-stage renal disease, 17 of whom (A 6 treated and B II untreated)
showed progression within 2.5 years after their index renal biopsy.
Table 5. Variables at renal biopsy index associated with rapid
progression to end-stage renal disease
8 100 2 4 6 8 10
Stable
no. (%)
End-stage renal
disease,
>5 mg/dl no. (%)
Rapid Rest of
progressions group
N = 17 N = 123 Significance
Sex M:F 15:2 78:45 <0.05a
24 hr Proteinuria g 14.8 8 7.5 4.5 <0001b
Serum
Creatinine mgldl
Cholesterol mgld/
Triglycerides mgldl
1.8 0.9
463 120
304 173
1.2 0.4
369 119
234 149
<0001"
<0.01"
<0.05"
a x2 test
b Two-sample t-test
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Fig. 4. Probability of surviving s'ithout developing end-stage renal
disease according to baseline proteinuria: group A, 24 patients, 0-3.4
g/24 hr; group B, 73 patients, 3.5-10 g/24 hr: and group C, 43 patients,
10 or more g/24 hr (P < 0.0001). A vs. B (NS). A vs. C (P < 0.001), and
B vs. C (P < 0.0001).
(15%) who had various outcomes for proteinuria (Table 6), and
proteinuria was variable in 7 (29%) of the 24 patients with
baseline nonnephrotic proteinuria. In the nonnephrotic group,
13 of 15 untreated patients and 4 of 9 treated patients were in
partial nephrotic remission, S treated patients had nephrotic-
range proteinuria, and, at last measurement, 2 untreated pa-
tients had persistent proteinuria (2.9 g/24 hr). These data
indicate the high degree of variability of proteinuria in idio-
pathic membranous nephropathy when this continuous variable
is analyzed long term.
Progression to end-stage renal disease was associated with a
level of baseline proteinuria of tO g or more per 24 hours (Fig.
4). By survival analysis, the probability of surviving without
renal failure was significantly worse when intervals of protein-
uria were compared among the nonnephrotic range (0 to 3.4 g124
hr) and the midnephrotic range (3.5 to 10 g/24 hr) and the severe
nephrotic range (10 or more g/24 hr). Only one patient with
proteinuria in the nonnephrotic range became persistently ne-
phrotic and developed end-stage renal disease, whereas two
others (one untreated and one treated) had renal insufficiency
(serum creatinine 2 to 5 mg/dl range) at last follow-up.
Variable blood pressure control in hypertensive patients
throughout the clinical course was related to a higher progres-
sion rate defined as the development of end-stage renal disease
or a doubling of serum creatinine level from baseline (Table 7)
(P < 0.05, log-rank test). No difference in the relationship of
hypertension and renal progression was noted between the
untreated and corticosteroid- or immunosuppressive-treated
groups.
Various cancers were found in 10 of 140 patients (7.1%),
including six in the treated and four in the untreated groups.
The relationship between diagnosis of the malignancies and the
index renal biopsies is shown in Figure 5.
Twenty-five of 140 patients (18%) died. Sixteen deaths were
nonrenal related—lO in the untreated and 6 in the treated group.
There were various causes of death: carcinomas (7), cardiovas-
cular (5), and miscellaneous (4). Nine patients died after renal
failure was established. In five untreated patients, four had been
on long-term dialysis and died of the following: Staphylococcus
sepsis (2), with seizures in one; cardiac arrhythmia (I); and
Time from renal biopsy, years
Fig. 5. Timing of diagnosis of malignant disease before and after date
of index renal biopsy in patients smith idiopathic mnemnhranous nephrop—
athy. *One patient (untreated group) had small cell carcinoma of the
lung diagnosed 4 years before, and a second primary, squamous cell
carcinoma of the lung diagnosed simultaneously with index renal
biopsy. Symbols are: ()treated: (•) untreated.
cerebrovascular accident (I). One uremic male patient died
without support of his renal failure. Four treated patients died,
two after being established on dialysis programs, and both after
surgery: one from an acutely perforated duodenal ulcer and the
other from an ischemic bowel. Two patients died after renal
transplantation, one from a ruptured ventricular aneurysm
within six months after allografting and a second two years after
transplant from acute hepatic necrosis due to recurrent HBs
antigen-positive hepatitis.
Discussion
These 140 patients with idiopathic membranous nephropathy
had characteristics of male predominance, an average age of 50
years, the nephrotic syndrome in 116 (83%), and hypertension
in 42 (30%) when their renal morphologic diagnosis was estab-
lished. Eighty-nine patients were not treated with corticosteroid
or immunosuppressive drugs and 51 patients received mainly
short-term treatment with prednisone, usually in a dosage of 60
mg/day for two months. A minority of treated patients also was
given meclofenamate or an immunosuppressive agent (mostly
cyclophosphamide). The clinical characteristics between un-
treated and treated patients were similar except for higher
serum triglyceride levels in the steroid-treated patients.
Five-year and 10-year patient survival rates were not signit'-
icantly different from expected survival nor were they different
between untreated and treated groups. Furthermore, survivor-
ship without death or end-stage renal failure combined was
similar between untreated and treated patients. We also empha-
size that the overall outcomes of renal function and proteinuria
were not different between untreated and treated patients, and
more than one-half of the patients were in either partial or
complete nephrotic remission and had stable renal function at
final follow-up. In this retrospective analysis, the different
therapeutic regimens may have biased the long-term ineffec-
tiveness of treatment that we observed. An obvious point to
underscore here is that treatment effects can only be truly
evaluated in well-designed, prospective clinical trials.
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Table 7. Hypertension at index renal biopsy and blood pressure control related to renal progression in untreated and treated patients with
idiopathic membranous nephropathy
Hyper- Renal Normo- Renal
tensive progressiona tensive progressionb
Group no. no. % no. no. %
Hypertension at baseline
Untreated 3! 10 32 58 8 14
Treated 23 6 26 28 6 21
Total 54 30 86 14 16
Blood pressure control in hypertensive group
Adequate' Variable
Untreated 17 4 24 14 6 43
Treated 17 2 12 6 4 67
Total 34 6 18 20 10 50
Hypertensive vs. normotensive progression, P = 0.08 (log-rank test); adequate vs. variable progression, P < 0.005 (log-rank test).
a Doubling serum creatinine level from baseline only (1); end-stage renal disease only (7); doubling serum creatinine + end-stage renal disease (8)
b Doubling serum creatinine level from baseline only (I); end-stage renal disease only (7); doubling serum creatinine + end-stage renal disease (6)
a Average blood pressure = 140/85 mm Hg or lower.
In analyzing variables at the time of the index renal biopsy,
we identified a subset of patients who were at high risk for a
rapid progression to end-stage renal disease occurring within
2.5 years after biopsy. These risks were male sex, elevated
serum creatinine level, and nephrotic syndrome with an average
urine protein excretion of 14.8 g/24 hr. There was a significant
correlation between renal progression and increasing levels of
baseline protein excretion. Hypertensive patients whose blood
pressure was variably controlled had more progressive renal
disease. Also, the issue of renal vein thrombosis was addressed
in 27 patients included in this review in a previously reported
prospective study in which no differences were found in renal
progression between those with and without renal vein throm-
bosis [341.
Concerning the favorable outcomes, the information pro-
vided in our review is quite similar to that recently reported in
three other series of large numbers of patients with idiopathic
membranous nephropathy that included those who were un-
treated [7, 11, 121. In the study with the largest number of
untreated patients, Noel et al [7] reported that only 10 of 116
patients (9%) developed end-stage renal disease of a total of 22
(19%) who had impaired renal function after an average fol-
low-up of 4.5 years. The low incidence of end-stage renal
disease is partly attributed to an inherently improved prognosis
found in their population that consisted of nearly 50% females
and younger patients, with 25% less than age 20 years at
diagnosis. The nephrotic syndrome was present in 76% of the
patients at onset. In the two other studies, actuarial 10-year
survival rates were 90% in a report from Japan [11] and 83% in
a study from Finland [12]. Sixty percent of the Japanese and
75% of the Finnish patients were nephrotic at onset of disease.
In both of these studies, there were no differences in patient
survival or renal function outcomes between untreated patients
and those treated with corticosteroids alone or combined with
cyclophosphamide [11, 12]. Previously reported long-term clin-
ical reviews [3—6, 81, including one of our own [41, also showed
that a majority of patients, regardless of treatment (primarily
with glucocorticoids), survived without terminal renal failure.
The cumulative results from all of these studies further support
the contention that patients with idiopathic inembranous
nephropathy have as good a prognosis irrespective of cortico-
steroid therapy, with or without cyclophosphamide, the pre-
dominant cytotoxic drug used, or no treatment other than
control of high blood pressure.
Treatment with corticocosteroids or immunosuppressive
drugs or both is supported best in two published clinical trials
[23, 251 conducted in nephrotic subjects but not necessarily a
high-risk population. Renal function was stabilized by the use of
alternate-day prednisone treatment (100 to 150 mg in a single
dose on alternate days for 2 months) in the collaborative study
of the adult nephrotic syndrome [23] and therapy with methyl-
prednisolone (I g intravenously for three days, then the oral
preparation at 0.4 mg/kg per day or prednisone 0.5 mg/kg per
day) followed by chlorambucil (0.2 mg/kg per day) in monthly
cycles for six months in the Italian multicenter trial [25]. Also,
in the Italian trial, remissions from the nephrotic syndrome
occurred more often in the treated than in the control group in
patients primarily with stage I and II lesions [251. Replications
are lacking for both of these treatment modalities, although two
trials of alternate-day prednisone treatment are under way in
Canada 135] and the United Kingdom (Cameron JS, personal
communication). In the Canadian trial, treatment with predni-
sone, 45 mg/rn2 on alternate days for six months, is being
compared with controls. In a preliminary report, equal numbers
of patients in the treated and control groups had developed
end-stage renal disease, but renal function, as assessed by
creatinine data, appeared to be more stable in treated patients
with stage I and II glomerular lesions [35]. There are no details
from the United Kingdom study. Incidentally, we found no
relationship between remission rates or progressive renal dis-
ease and the composite stage of index renal biopsies.
A major concern in the two fully reported clinical trials is
what appears to be a higher than expected progression rate in
the control groups. Because of a relatively short follow-up
period of two to three years, the continuous variable of a
doubling rate of serum creatinine [231 or change in the recipro-
cal of the plasma creatinine levels [25, 361 was the determinant
used for effects of treatment on renal function. A comparison of
renal progression by change in serum creatinine level can be
made between untreated nephrotic patients in the studies by
Noel et aT [7] and the present study and control populations in
the clinical trials (Table 8). For patients at risk after two years,
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Table 8. Loss of renal function determined by a doubling of serum
creatinine level in nephrotic patients with idiopathic membranous
nephropathy after 2 years of treatment versus placebo or control and
nontreatment
Patients in whom
serum creatinine
doubled after 2
years
Study Treatment
No. at
risk No. %
Noel et a! [7 and 231 Nontreatment
í Alternate-day
Collaborative Study [23]j prednisone
. Placebo
í Methylprednisolone
Ponticelli et at [361 + chlorambucil
Control
Present study Nontreatment
59 7 12
20 2 10
25 II 44
34 I 3
31 7 23
74 9 12
the serum creatinine level doubling rates were nearly two times
higher in the controls in the Italian trial [361 and almost fourfold
higher in the placebo group in the collaborative study [231,
compared with those found by Noel et al [7] and ourselves in
untreated patients. Moreover, the doubling rates were compa-
rable between alternate-day prednisone-treated patients in the
collaborative trial [23] and untreated patients in the report of
Noel et al [7] and in our results. The combined methylprednis-
olone and chlorambucil-treated group in the Italian multicenter
trial [361 had a somewhat lower progression than was demon-
strated in untreated patients. However, the long-term effects of
this combination of treatments on progression to end-stage
renal disease is not known at this time because of a relatively
short follow-up period. The major message in the above com-
parison, however, is to show that the favorable effect of
treatment on renal function in the clinical trials may be apparent
because of the relatively high progression rates that were
observed in their control groups.
Final consideration is given to the identification of risk
factors in patients who had progressive loss of renal function.
Both in our review and in that of Davison et al [10], the
deterioration of renal function was largely distinguishable from
those with stable renal function after approximately 2.5 years.
Furthermore, Davison et al [10] identified similar risks to ours
that were associated with rapid progression, which included
severely nephrotic males who had impaired renal function at the
time of diagnosis. Slower progression rates, in our study and in
that of Davison et al [10], were found in a smaller group of
patients with persistent nephrotic syndrome. In the study by
Kida et al [11], a steady state was reached in the distribution of
patients who remained nephrotic and those who were in remis-
sion from the nephrotic syndrome after five years, The majority
who were in nephrotic remission had stable renal function
thereafter, as also demonstrated in our patients who entered
remission.
Evidence of malignancy in 7.1% of our patients is no greater
or less than that reported in patients with membranous
nephropathy in the medical literature [371. The association
between carcinomas and membranous lesions is presumably
mediated by immune complexes comprised in part of tumor-
associated antigens [1, 2, 37]. We can say nothing further about
the reported association between malignancies and membra-
nous nephropathy other than to refer to an analysis of another
purported association between a paraneoplastic condition,
polymyositis-dermatomyositis, and malignancy. Lakhanpal and
associates [38] reported that patients with polymyositis-
dermatomyositis had more malignant disease (25%) than the
carefully matched control population (17%), but that the differ-
ence was not statistically significant. The slight excess of cancer
seen among all the patients was contributed to by the most
distant referral and may best be explained on the basis of
referral bias. This study was also conducted at the Mayo Clinic
and included patients from the approximate geographic area
from which our patients were derived. Thus, by inference, our
frequency of 7.1% is actually lower than the 17% found by
Lakhanpal and associates [38] in their control population.
Our clinical review supports the recent studies that showed
normal patient survival and low renal progression rates in
various populations of patients with idiopathic membranous
nephropathy. Furthermore, we identified a subset of high-risk
patients who progressed to renal failure in a relatively short
time. It is in these readily identifiable patients that prospective
clinical trials should be undertaken to test encouraging new
therapies.
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